Pharvaris to seek FDA approval of HAE treatment deucrictibant
Pharvaris expects to ask the U.S. Food and Drug Administration to approve deucrictibant as an on-demand treatment for hereditary angioedema (HAE) attacks next year. The application will cover the immediate-release (IR) capsule formulation of the therapy, which is intended to control swelling attacks as they occur. The submission…